A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

J. M. McKenney, J. D. Proctor, S. Harris and V. M. Chinchili
School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.

OBJECTIVE--To compare escalating doses of immediate-release (IR) and sustained-release (SR) niacin for effectiveness in reducing levels of low-density lipoprotein cholesterol and triglycerides and increasing levels of high-density lipoprotein cholesterol, and for the occurrence of adverse reactions, especially hepatotoxicity. DESIGN--Randomized, double-blind, parallel comparison of IR and SR niacin administered sequentially at 500, 1000, 1500, 2000, and 3000 mg/d, each for 6 weeks. SETTING--Cholesterol research center. PATIENTS--Forty-six adults, 23 in each group, with low-density lipoprotein cholesterol levels greater than 4.14 mmol/L (160 mg/dL) after 1 month of a step 1 National Cholesterol Education Program diet. OUTCOME MEASURES--Fourteen-hour fasting lipid and lipoprotein cholesterol levels, results of clinical laboratory tests, a symptom questionnaire, and withdrawal rates. RESULTS--The SR niacin lowered low-density lipoprotein cholesterol levels significantly more than IR niacin did at the dosage of 1500 mg/d and above, while IR niacin increased high-density lipoprotein cholesterol levels significantly more than SR niacin did at all dosage levels. The reduction in triglyceride levels was similar with IR and SR niacin. Nine (39%) of the 23 patients assigned to the IR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were vasodilatory symptoms, fatigue, and acanthosis nigricans. Eighteen (78%) of the 23 patients assigned to the SR dosage form withdrew before completing the 3000-mg daily dose; the most common reasons for withdrawal were gastrointestinal tract symptoms, fatigue, and increases in levels of liver aminotransferases, often with symptoms of hepatic dysfunction. None of the patients taking IR niacin developed hepatotoxic effects, while 12 (52%) of the 23 patients taking SR niacin did. CONCLUSION--The SR form of niacin is hepatotoxic and should be restricted from use. The IR niacin is preferred for the management of hypercholesterolemia but can also cause significant adverse effects and should be given only to patients who can be carefully monitored by experienced health professionals.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors
Richman et al.
J. Biol. Chem. 2007;282:18028-18036.
ABSTRACT | FULL TEXT  

Antilipolytic Activity of a Novel Partial A1 Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic Acid
Dhalla et al.
J. Pharmacol. Exp. Ther. 2007;321:327-333.
ABSTRACT | FULL TEXT  

Niaspan(R): creating a new concept for raising HDL-cholesterol
McGovern
Eur Heart J Suppl 2005;7:F41-F47.
ABSTRACT | FULL TEXT  

Raising HDL-C and lowering triglycerides: benefits beyond LDL-C modification
Shepherd
British Journal of Diabetes & Vascular Disease 2005;5:S12-S16.
ABSTRACT  

Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT  

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia
Meagher
J Am Board Fam Med 2004;17:424-437.
ABSTRACT | FULL TEXT  

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT | FULL TEXT  

The Metabolic Syndrome: Pathophysiology, Clinical Relevance, and Use of Niacin
Ito
The Annals of Pharmacotherapy 2004;38:277-285.
ABSTRACT | FULL TEXT  

Varying Cost and Free Nicotinic Acid Content in Over-the-Counter Niacin Preparations for Dyslipidemia
Meyers et al.
ANN INTERN MED 2003;139:996-1002.
ABSTRACT | FULL TEXT  

Medical Management of Hyperlipidemia/Dyslipidemia
Kreisberg and Oberman
J. Clin. Endocrinol. Metab. 2003;88:2445-2461.
FULL TEXT  

Niacin-ER and Lovastatin Treatment of Hypercholesterolemia and Mixed Dyslipidemia
Yim and Chong
The Annals of Pharmacotherapy 2003;37:106-115.
ABSTRACT | FULL TEXT  

References
Circulation 2002;106:3373-3421.
FULL TEXT  

Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes: Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
Grundy et al.
Arch Intern Med 2002;162:1568-1576.
ABSTRACT | FULL TEXT  

Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol
Sakai et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1783-1789.
ABSTRACT | FULL TEXT  

Extended-Release Niacin vs Gemfibrozil for the Treatment of Low Levels of High-Density Lipoprotein Cholesterol
Guyton et al.
Arch Intern Med 2000;160:1177-1184.
ABSTRACT | FULL TEXT  

Drug Treatment of Lipid Disorders
Knopp
NEJM 1999;341:498-511.
FULL TEXT  

New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol
Harper and Jacobson
Arch Intern Med 1999;159:1049-1057.
ABSTRACT | FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

HEPATOTOXICITY OF SUSTAINED-RELEASE NIACIN
JWatch General 1994;1994:6-6.
FULL TEXT